Atara Biotherapeutics(ATRA) - 2025 Q4 - Annual Results
Atara Biotherapeutics(US:ATRA)2026-01-12 21:00Financial Position - As of December 31, 2025, Atara Biotherapeutics reported its cash, cash equivalents, and short-term investments, although specific figures were not disclosed in the preliminary estimate[6] Regulatory Challenges - The U.S. FDA issued a Complete Response Letter for the EBVALLO™ (tabelecleucel) Biologics License Application, indicating regulatory challenges for the product[7]